Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06276491 · ClinicalTrials.gov registry record · Phase 1
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
A Phase 1 study of Ovarian Cancer and Endometrial Cancer, sponsored by Xencor.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 282
- Enrollment target
- 16
- Study locations
NCT06276491 is a Phase 1 study of Ovarian Cancer and Endometrial Cancer that is actively recruiting participants, run by Xencor. The registered enrollment target is 282 participants, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (61% lower). The trial reports 16 study locations across 13 states.
The verdict
NCT06276491, a Phase 1 study of Ovarian Cancer and Endometrial Cancer, is actively recruiting participants, sponsored by Xencor.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 282 participants
- Enrollment target
- 16
- Study locations
Study Summary
The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 on tumor outcomes.
Conditions Studied
Interventions
- BIOLOGICAL XmAb541
Study Locations (16)
California
- City of Hope - Duarte
- Stanford - Palo Alto
- University of California - San Francisco
New York
- Icahn School of Medicine at Mount Sinai - New York
- Montefiore Einstein Comprehensive Cancer Center - The Bronx
Florida
- Moffitt Cancer Center - Tampa
Georgia
- Winship Cancer Institute, Emory University - Atlanta
Illinois
- University of Chicago Medical Center - Chicago
Indiana
- Indian University Melvin and Bren Simon Comprehensive Cancer Center - Indianapolis
Michigan
- Karmanos Cancer Institute - Detroit
New Jersey
- The John Theruer Cancer Center at Hackensack University Medical Center - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 282 participants |
| Start Date | 2024-04-04 |
| Est. Completion | 2028-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06276491
The ClinicalTrials.gov registry entry for NCT06276491 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 282 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (61% lower). The listed sponsor is Xencor, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which XmAb541 is the first listed.
NCT06276491 reports 16 study locations spanning 13 distinct geographic areas - top geographies include California, New York, Florida.
Frequently Asked Questions
What is clinical trial NCT06276491 about?
NCT06276491 is a clinical study titled "Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors". The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 on tumor outcomes.
What is the current status of trial NCT06276491?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 282 participants. The study started on 2024-04-04. Estimated completion is 2028-12.
What conditions does trial NCT06276491 study?
This clinical trial studies the following conditions: Ovarian Cancer, Endometrial Cancer, Germ Cell Tumor, Testicular Germ Cell Tumor, Ovarian Germ Cell Tumor.
What interventions are being tested in trial NCT06276491?
The interventions under investigation include: XmAb541 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06276491?
This trial is sponsored by Xencor, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06276491 being conducted?
This trial has 16 study locations across California, Florida, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.